Microbiote intestinal et réponses aux thérapies anti-tumorales

Vétizou, Marie; Daillère, Romain; Zitvogel, Laurence

doi:10.1051/medsci/20163211013

Cited by 17 publications

(4 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This complexity in immune response and microbiome diversity is also evident in recent human and mouse studies that demonstrate an impact of specific bacteria on the antitumor effects of treatments with CTLA-4 or PD1/PD-L1 blockade (51,54,(59)(60)(61). Elimination of bacterial species by broad-spectrum antibiotics or fecal transfer from immunotherapy-resistant patients to germfree mice eliminated the response to immune checkpoint therapy.…”

Section: Methodsmentioning

confidence: 93%

Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response

Uribe‐Herranz¹,

Rafail²,

Beghi³

et al. 2019

Journal of Clinical Investigation

175

147

View full text Add to dashboard Cite

Oral vancomycin treatment enhances the direct and abscopal antitumor effects of hypofractionated RT in preclinical melanoma and lung/cervical tumor models. Given the role of the gut microbiota in modulating immune cells that are also known to be involved in the response to RT, we examined whether the microbiota-regulated systemic immune response contributes to the RT-mediated anticancer immune response. The effects of oral vancomycin treatment are localized and impact the gut microbiota directly without any known systemic effects (21-23). Vancomycin (mostly targeting gram-positive bacteria) or a neomycin/metronidazole (Neo/Met) regimen (mostly targeting gram-negative bacteria

show abstract

Section: Methodsmentioning

confidence: 93%

Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response

Uribe‐Herranz¹,

Rafail²,

Beghi³

et al. 2019

Journal of Clinical Investigation

175

147

View full text Add to dashboard Cite

show abstract

“…Cyclophosphamide (the most used molecule in the chemotherapeutic treatment of breast cancer) causes a shortening of intestinal villi and impermeability of the intestinal barrier, which facilitates the translocation of commensal bacteria such as Enterococcus hirae and Barnesiella intestinihominis to secondary lymphoid organs [ 60 ]. Once in the lymphoid organs, E. hirae helps to mediate CTX-driven accumulation of type 17 and type 1 T helper cell response, and B. intestinihominis increases systemic levels of a polyfunctional subset of cytotoxic CD 8 + T cells [ 31 , 61 ]. Despite the crucial role of the gut microbiota in improving the chemotherapeutic response, anticancer agents can be toxic to the intestinal microbiome and cause its alteration.…”

Section: Discussionmentioning

confidence: 99%

Fecal Metabolic Profiling of Breast Cancer Patients during Neoadjuvant Chemotherapy Reveals Potential Biomarkers

Zidi¹,

Souai²,

Raies

et al. 2021

Molecules

View full text Add to dashboard Cite

Breast cancer (BC) is the most common form of cancer among women worldwide. Despite the huge advancements in its treatment, the exact etiology of breast cancer still remains unresolved. There is an increasing interest in the role of the gut microbiome in modulating the anti-cancer therapeutic response. It seems that alteration of the microbiome-derived metabolome potentially promotes carcinogenesis. Taken together, metabolomics has arisen as a fascinating new omics field to screen promising metabolic biomarkers. In this study, fecal metabolite profiling was performed using NMR spectroscopy, to identify potential biomarker candidates that can predict response to neoadjuvant chemotherapy (NAC) for breast cancer. Metabolic profiles of feces from patients (n = 8) following chemotherapy treatment cycles were studied. Interestingly, amino acids were found to be upregulated, while lactate and fumaric acid were downregulated in patients under the second and third cycles compared with patients before treatment. Furthermore, short-chain fatty acids (SCFAs) were significantly differentiated between the studied groups. These results strongly suggest that chemotherapy treatment plays a key role in modulating the fecal metabolomic profile of BC patients. In conclusion, we demonstrate the feasibility of identifying specific fecal metabolic profiles reflecting biochemical changes that occur during the chemotherapy treatment. These data give an interesting insight that may complement and improve clinical tools for BC monitoring.

show abstract

“…Cet effet protecteur a été attribué à l'induction de la réponse TH17 mais aussi, de façon plus indirecte, profondément réduites lors d'un traitement antibiotique. L'étude de souris gnotoxéniques montre aussi que la nature et l'intensité des réponses immunes adaptatives dépendent de la composition du microbiote et particulièrement de la présence de la bactérie segmentée filamenteuse (SFB) [42] (➜). Contrairement à la majorité des bactéries commensales 5 qui induisent une réponse IgA relativement modeste et des réponses T dominées par des réponses T régulatrices, notamment dans le côlon [18,[26][27][28], la SFB joue un rôle privilégié dans la maturation post-natale des réponses immunes innées et adaptatives chez son hôte [18,22] (Figure 2).…”

Section: Synthèse Revuesunclassified

Microbiote intestinal et développement du système immunitaire

Gaboriau-Routhiau

Cerf‐Bensussan

2016

Med Sci (Paris)

View full text Add to dashboard Cite

Microbiote intestinal et réponses aux thérapies anti-tumorales

Cited by 17 publications

References 57 publications

Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response

Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response

Fecal Metabolic Profiling of Breast Cancer Patients during Neoadjuvant Chemotherapy Reveals Potential Biomarkers

Microbiote intestinal et développement du système immunitaire

Contact Info

Product

Resources

About